Insulet Corporation Stock News

Medical stocks are holding up amid economic and market uncertainty. The post 5 S&P 500 Stocks Showing Strength As Recession Fears Rise appeared first on Investor's Business Daily.

Insulet (PODD) possesses solid growth attributes, which could help it handily outperform the market.

Insulet (PODD) witnesses continued uptake of Omnipod through the U.S. pharmacy channel.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Thanks to the Fed's willingness to pause its interest rate hikes, it's prudent for investors to place their bets on growth stocks like Comfort Systems USA (FIX), Hershey (HSY), Wynn Resorts (WYNN), In

Insulet achieved another remarkable fiscal year, driven by the successful adoption of Omnipod 5, which is being used by growing diabetic patients globally. The management expects continued growth in i

Insulet (PODD) could produce exceptional returns because of its solid growth attributes.

S&P Indices said late Friday that Insulet Corp. PODD, -0.97% will replace Silicon Valley Bank parent SVB Financial Group SIVB, -60.41% in the S&P 500 index SPX, -1.45% at the open on Wednesday. The ba

Insulet (PODD) could produce exceptional returns because of its solid growth attributes.

Insulet (PODD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Insulet's (PODD) Q4 performance benefits from record quarterly U.S. and Total Omnipod new customer starts.

Insulet Corporation (NASDAQ:PODD ) Q4 2022 Results Conference Call February 23, 2023 4:30 PM ET Company Participants Deborah Gordon - VP, IR Jim Hollingshead - President, CEO Wayde McMillan - EVP, CFO

Insulet (PODD) delivered earnings and revenue surprises of 129.17% and 11.91%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Insulet Corporation has been a long-term steady growth play in the diabetes delivery space. I like the strong secular growth, but margins and dilution mean that the share price advancement has far out

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management